Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 0.76% 66.50 64.00 69.00 0.00 0.00 0.00 0.00 07:37:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.4 -0.8 -2.0 - 31

IXICO plc Issue of Equity

28/08/2019 12:21pm

UK Regulatory (RNS & others)

Ixico (LSE:IXI)
Historical Stock Chart

3 Months : From Aug 2019 to Nov 2019

Click Here for more Ixico Charts.


RNS Number : 4348K


28 August 2019

28 August 2019


("IXICO" or the "Company")

Issue of Equity

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 37,647 new ordinary shares of 0.1p each ("New Shares") to satisfy the exercise of options.

The New Shares are expected to be admitted to trading on AIM on 29 August 2019.

Total voting rights

Application has been made for admission to trading on AIM of 37,647 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 29 August 2019, following which there will be in total 46,814,647 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

For further information please contact:

 IXICO plc                                        +44 (0) 20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                +44 (0) 20 7397 8900 
 Giles Balleny / Max Gould (Corporate Finance) 
 Michael F Johnson / Russell Kerr (Sales) 
 Optimum Strategic Communications                +44 (0) 203 950 9144 
 Mary Clark / Anne Marieke Ezendam / Supriya 


IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

August 28, 2019 07:21 ET (11:21 GMT)

1 Year Ixico Chart

1 Year Ixico Chart

1 Month Ixico Chart

1 Month Ixico Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191113 08:02:45